ArticleCancer innovation2024
Integrative analyses identified gap junction beta-2 as a prognostic biomarker and therapeutic target for breast cancer.
Di Zhang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
5 papers cite it
this papercites it